SGS, a testing, inspection and certification company, has acquired CDMO Quay Pharma.
The deal will provide Quay with investment to grow its range of services through various stages of pharmaceutical clinical development, from pre-clinical to formulation, dosage form design and optimisation, as well as clinical trial manufacture and supply.
In particular, it’s hoped to enhance the development of the company’s work in live biotherapeutics, and its expansion in the United States, where it recently opened a sales office in addition to a manufacturing facility in the Greater Boston area.
“This is an exciting and significant milestone for Quay,” said the company’s CEO Maireadh Pedersen. “As part of SGS, we will be able to accelerate our growth strategy and further develop our range of services, with the introduction of additional capabilities such as biopharmaceutical analysis and specialist microbiological capabilities.
“At the same time, we will retain our existing management and dedicated specialist teams to ensure we continue to offer our clients the highest levels of service, expertise and technical focus, coupled with a flexible approach, on which our success has been built.”
Quay will become part of SGS Health Science and be the company’s global centre for formulation, research and development. The acquisition is part of the company’s strategy to increase its scope of services across the health science supply chain.
Frankie Ng, CEO of SGS said: “This acquisition supports our strategic evolution by further aligning our global network ever more closely to TIC megatrends. Quay Pharma adds a significant level of competence to the group and allows us to offer more comprehensive and complex, high value-added services to our customers.”
